Radiochemistry Laboratory Core

放射化学实验室核心

• 批准号: 6944166
• 负责人: Joseph G Rajendran
• 金额: $ 44.91万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6944166
• 关键词: antitumor antibody; bioimaging /biomedical imaging; biomedical facility; imaging /visualization /scanning; immunologic substance development /preparation; neoplasm /cancer radioimmunotherapy; pharmacokinetics; radiochemistry; radiopharmacology

In core B, nuclear imaging and radiochemistry services for all the projects will be provided. In pre-clinical studies, the laboratory will evaluate each antibody lot, as well as new antibodies for tolerance to labeling at trace, as well as high specific activity levels for therapy. For these activities, the Core will prepare high specific activity therapy doses for patient treatment. As a part of all these procedures, all aspects of quality control for the radiopharmaceuticals will be maintained and documented. The core will also support nuclear medicine imaging procedures to observe biodistribution of radiolabeled antibody in patients and primate studies and translate that data into radiation dose estimates for treatment. Members of the Core will supervise the administration of therapy doses of radiolabeled antibodies.

在核心B中，将为所有项目提供核成像和放射化学服务。在临床前研究中，实验室将评估每种抗体批次，以及用于痕量标记的新抗体，以及用于治疗的高特定活性水平。对于这些活动，核心将为患者治疗准备高特异性的活动疗法剂量。作为所有这些程序的一部分，放射性药物的质量控制的所有方面都将是 维护和记录。核心还将支持核医学成像程序，以观察患者和灵长类动物研究中放射性标记抗体的生物分布，并将数据转化为治疗的辐射剂量估计。核心成员将监督放射标记抗体的治疗剂量的给药。